North Carolina biologics regulations.

Who may administer PRP, exosomes and stem cells in North Carolina, and which agencies to check.

A physician at a desk reading regulatory documents

Who may administer biologics in North Carolina?

In North Carolina, only licensed medical providers such as physicians (MD or DO) are authorized to administer stem cell treatments. Provider Training Clinics should ensure that all staff involved in biologic treatments have training in administering HCT/P products.

Official sources

North Carolina compliance guide.

FDA Compliance

The U.S. Food and Drug Administration (FDA) regulates human cells, tissues, and cellular and tissue-based products (HCT/P) under 21 CFR Part 1271. North Carolina clinics providing stem cell therapies should understand that most HCT/P products must meet stringent safety and efficacy requirements. For detailed FDA guidance, refer to FDA's Biologics Guidance Documents.

North Carolina State Regulations

North Carolina clinics offering biologic treatments must comply with state health and licensing requirements. To learn more about state-specific requirements, visit the North Carolina Department of Health and Human Services website. Understanding these regulations helps clinics ensure compliance while providing accessible and safe therapies.

Provider Qualifications

In North Carolina, only licensed medical providers such as physicians (MD or DO) are authorized to administer stem cell treatments. Visit the North Carolina Medical Board to verify provider credentialing requirements.

Provider Training

Clinics should ensure that all staff involved in biologic treatments have training in administering HCT/P products. Completion of specialized courses or certifications in regenerative medicine can further enhance provider readiness and compliance.

Patient Informed Consent

Informed consent is essential for stem cell therapies due to their experimental nature. Clinics must provide patients with a comprehensive consent form detailing potential risks, benefits, alternative treatments, and an acknowledgment of the therapy’s investigational status. Templates are often customizable to meet North Carolina’s legal standards and can help manage patient expectations effectively.

Additional Compliance Considerations

Pre-Treatment and Post-Treatment Protocols

Clinics should establish and document standard operating procedures (SOPs) for both pre-treatment screenings and post-treatment follow-ups. These protocols help maintain patient safety and ensure thorough records of patient responses and any adverse effects.

Medical Liability Insurance

Providers in North Carolina should maintain liability insurance that covers biologic treatments. This insurance is essential for managing potential legal claims and demonstrating commitment to patient safety and compliance.

Marketing Compliance

Marketing materials for biologics in North Carolina must comply with both FDA and state advertising guidelines, avoiding unverified claims of efficacy. Promotional content should clearly disclose the investigational nature of stem cell therapies and adhere to FDA advertising standards.

This guide is a general summary to help clinics understand compliance requirements for biologics in North Carolina. It is not legal advice. Regulations change; consult legal counsel and the agencies above before acting on it.

North Carolina: common questions.

Who can administer stem cells, PRP and exosomes in North Carolina?
In North Carolina, only licensed medical providers such as physicians (MD or DO) are authorized to administer stem cell treatments. Provider Training Clinics should ensure that all staff involved in biologic treatments have training in administering HCT/P products. This is a general summary, not legal advice. Confirm with the state board.
Are stem cell and exosome therapies FDA-approved in North Carolina?
FDA rules are federal, so they apply in North Carolina as everywhere else. Exosome and stem cell therapies are not FDA-approved for therapeutic use, and PRP applications are considered off-label.
Do I need an IRB-approved study to offer biologics in North Carolina?
Investigational treatment belongs inside a reviewed study with proper informed consent. IRB review is not FDA authorisation: culture-expanded and other more-than-minimally-manipulated cell products generally need an IND before use in people.
How do I start offering biologics in North Carolina?
Start with the live webinar, then a discovery call and live training. After that we verify your North Carolina licence, protocol, product sourcing, consent process and advertising before you are listed for patient inquiries.

Practising in North Carolina? Start with the webinar.

Live on Zoom, Tuesdays at 12:00 PM ET. See how the model works before you commit to anything.